Vyome Holdings (HIND) Non-Current Deffered Revenue (2017 - 2018)
Vyome Holdings (HIND) posted quarterly Non-Current Deffered Revenue of $48000.0 for Q4 2018, up 269.23% year-over-year from $13000.0 in Q4 2017, and up 4.35% quarter-over-quarter from $46000.0 in Q3 2018.
Vyome Holdings (HIND) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends
Vyome Holdings' Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $48000.0 for Q4 2018.
- In Q4 2018, Non-Current Deffered Revenue rose 269.23% year-over-year to $48000.0; the TTM figure through Dec 2018 stood at $48000.0 (up 269.23% YoY), while the FY2018 annual figure was $48000.0, up 269.23% from the prior year.
- Non-Current Deffered Revenue for Q4 2018 stood at $48000.0, up from $46000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $48000.0 in Q4 2018, with the low at $13000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 48,000.00 |
| Sep 30, 2018 | 46,000.00 |
| Jun 30, 2018 | 44,000.00 |
| Dec 31, 2017 | 13,000.00 |
| Sep 30, 2017 | 26,000.00 |
| Jun 30, 2017 | 39,000.00 |